Foresite Capital Management Iv, LLC Lyell Immunopharma, Inc. Transaction History

Foresite Capital Management Iv, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.48 - $0.74 $3.69 Million - $5.69 Million	7,682,999 Added 92.29%	16,007,999 $8.64 Million
Q4 2023 Feb 13, 2024	SELL	$1.39 - $2.35 $639,140 - $1.08 Million	-459,813 Reduced 5.23%	8,325,000 $16.2 Million
Q3 2023 Nov 13, 2023	SELL	$1.45 - $3.35 $1.33 Million - $3.07 Million	-915,187 Reduced 9.43%	8,784,813 $12.9 Million
Q2 2023 Aug 11, 2023	SELL	$1.89 - $3.86 $567,000 - $1.16 Million	-300,000 Reduced 3.0%	9,700,000 $30.8 Million
Q3 2022 Nov 14, 2022	SELL	$5.54 - $8.27 $18.2 Million - $27.1 Million	-3,282,181 Reduced 24.71%	10,000,000 $73.3 Million
Q2 2021 Aug 16, 2021	BUY	$15.99 - $16.89 $212 Million - $224 Million	13,282,181 New	13,282,181 $216 Million

39.5M

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $2.62B
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iv, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iv, LLC with notifications on news.